Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shigehisa Kitano

Showing results (141-150 of 150) with videos related to

Pageof 15
Sort By:
You have reached the last page of results.This site can display upto 150 results.
International Journal of Cancer|February 2, 2023
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcomaMikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, et al.
Journal of Clinical Medicine|August 9, 2019
Approach to the Adult Acute Lymphoblastic Leukemia PatientValentina Sas, Vlad Moisoiu, Patric Teodorescu, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
Journal for Immunotherapy of Cancer|June 29, 2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndromeMikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, et al.
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.
Cancer Immunology Research|July 8, 2025
EML4-ALK Rearrangement Creates a Distinctive Myeloid Cell-Dominant Immunosuppressive Microenvironment in Lung CancerKosuke Arai, Yukari Nishito, Hideaki Mizuno, et al.
Cancer Letters|February 21, 2026
MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinomaHironori Fukuda, Kosuke Arai, Eri Hashimoto, et al.
Cancer Research Communications|June 28, 2023
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic AlterationsKazunori Aoki, Yukari Nishito, Noriko Motoi, et al.
Cancer Science|March 25, 2024
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironmentsHironori Fukuda, Kosuke Arai, Hideaki Mizuno, et al.
The New England Journal of Medicine|March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic CancerWungki Park, Anup Kasi, Alexander I Spira, et al.
Pageof 15

Showing results (141-150 of 150) with videos related to

Sort By:
Pageof 15
You have reached the last page of results.This site can display upto 150 results.
International Journal of Cancer|February 2, 2023
A phase 1 trial of NY-ESO-1-specific TCR-engineered T-cell therapy combined with a lymph node-targeting nanoparticulate peptide vaccine for the treatment of advanced soft tissue sarcomaMikiya Ishihara, Yoshihiro Nishida, Shigehisa Kitano, et al.
Journal of Clinical Medicine|August 9, 2019
Approach to the Adult Acute Lymphoblastic Leukemia PatientValentina Sas, Vlad Moisoiu, Patric Teodorescu, et al.
The New England Journal of Medicine|March 9, 2012
Immunologic correlates of the abscopal effect in a patient with melanomaMichael A Postow, Margaret K Callahan, Christopher A Barker, et al.
Journal for Immunotherapy of Cancer|June 29, 2022
NY-ESO-1-specific redirected T cells with endogenous TCR knockdown mediate tumor response and cytokine release syndromeMikiya Ishihara, Shigehisa Kitano, Shinichi Kageyama, et al.
Future Oncology (London, England)|March 4, 2026
Beamion PANTUMOR-1: rationale and design of a Phase II trial of zongertinib in HER2-overexpressed/amplified or <i>HER2</i>-mutant solid tumorsAlison M Schram, John J Park, Antoine Italiano, et al.
Cancer Immunology Research|July 8, 2025
EML4-ALK Rearrangement Creates a Distinctive Myeloid Cell-Dominant Immunosuppressive Microenvironment in Lung CancerKosuke Arai, Yukari Nishito, Hideaki Mizuno, et al.
Cancer Letters|February 21, 2026
MIF-CD74 axis facilitates MDSC infiltration in the tumor microenvironment of pancreatic ductal adenocarcinomaHironori Fukuda, Kosuke Arai, Eri Hashimoto, et al.
Cancer Research Communications|June 28, 2023
Tumor-infiltrating Leukocyte Profiling Defines Three Immune Subtypes of NSCLC with Distinct Signaling Pathways and Genetic AlterationsKazunori Aoki, Yukari Nishito, Noriko Motoi, et al.
Cancer Science|March 25, 2024
Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironmentsHironori Fukuda, Kosuke Arai, Hideaki Mizuno, et al.
The New England Journal of Medicine|March 25, 2026
Setidegrasib in Advanced Non-Small-Cell Lung Cancer and Pancreatic CancerWungki Park, Anup Kasi, Alexander I Spira, et al.
Pageof 15